-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LdU9bla1lIbkw+H27m/I2bunQS0gs1Odibzv0gb3geo9zbRPz+RKp0nAoNo2W349 n03chMADL+KxIx0aIeiT1Q== 0000912057-96-013179.txt : 19960627 0000912057-96-013179.hdr.sgml : 19960627 ACCESSION NUMBER: 0000912057-96-013179 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19960620 ITEM INFORMATION: Other events ITEM INFORMATION: Resignations of registrant's directors FILED AS OF DATE: 19960626 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: CORTEX PHARMACEUTICALS INC/DE/ CENTRAL INDEX KEY: 0000849636 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330303583 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17951 FILM NUMBER: 96586047 BUSINESS ADDRESS: STREET 1: 15241 BARRANCA PKWY CITY: IRVINE STATE: CA ZIP: 92718 BUSINESS PHONE: 7147273157 MAIL ADDRESS: STREET 2: 15241 BARRANCA PARKWAY CITY: IRVINE STATE: CA ZIP: 92718 8-K 1 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 20, 1996 -------------- CORTEX PHARMACEUTICALS, INC. ------------------------------------------------------ (Exact name of registrant as specified in its charter) Delaware 0-17951 33-0303583 --------------------------------------------------------------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No) 15241 Barranca Parkway, Irvine, California 92718 --------------------------------------------------------------- (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (714) 727-3157 -------------- Not Applicable ----------------------------------------------------------------- (Former name or former address, if changed since last report) Page 1 of 4 Exhibit Index on Page 3 ITEM 5. OTHER EVENTS On June 20, 1996, Cortex Pharmaceuticals, Inc. (the "Company") announced its intention to make a private placement of its Common Stock. The Company intends to raise $7 to $10 million in a private placement of common stock to accredited individual and institutional investors pursuant to Regulation D under the Securities Act of 1933, as amended. The Company said that it intends to use the proceeds for research and development, including the further clinical development of its AMPAKINE-TM- compounds for the potential treatment of Alzheimer's disease and schizophrenia, and for general corporate working capital purposes. No other terms were disclosed. ITEM 6. EXHIBITS Exhibits: 21 Press Release dated June 20, 1996. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CORTEX PHARMACEUTICALS, INC. Date: June 26, 1996 By: /s/D. Scott Hagen ----------------------------------------------- D. Scott Hagen Vice President and Chief Financial Officer 2 EXHIBIT INDEX Sequential Exhibits Description Page No. -------- ----------- -------- 21 Press release dated 4 June 20, 1996 3 -----END PRIVACY-ENHANCED MESSAGE-----